I Ojanguren1,2, M J Cruz3,4, A Villar1, M Barrecheguren1, F Morell1,2, X Muñoz1,2,5. 1. Respiratory Service, Department of Medicine, Vall d'Hebron University Hospital, Autonomous University of Barcelona, Passeig Vall d'Hebron, 119, 08035, Barcelona, Catalonia, Spain. 2. CIBER Enfermedades Respiratorias (Ciberes), Barcelona, Spain. 3. Respiratory Service, Department of Medicine, Vall d'Hebron University Hospital, Autonomous University of Barcelona, Passeig Vall d'Hebron, 119, 08035, Barcelona, Catalonia, Spain. mj.cruz@vhir.org. 4. CIBER Enfermedades Respiratorias (Ciberes), Barcelona, Spain. mj.cruz@vhir.org. 5. Department of Cell Biology, Physiology and Immunology, Autonomous University of Barcelona, Barcelona, Catalonia, Spain.
Abstract
BACKGROUND: There is very little evidence of the utility of the exhaled fraction of NO (FeNO) for the diagnosis of interstitial lung disease and nearly all of it is related with connective tissue disease. Some authors have suggested that in patients with hypersensitivity pneumonitis (HP), evolution to pulmonary fibrosis may be mediated by a Th2 mechanism, which could redound in a potential utility of FeNO. The aim of this study was to investigate the values of FeNO before and after antigenic exposure with the specific inhalation challenge (SIC) and to analyze its potential utility for the diagnosis of HP. METHODS: It was a prospective, cross-sectional study of all patients older than 18 years referred to our center for suspected chronic HP between May 2012 and May 2014 and who underwent a SIC. FeNO was collected before and after SIC. RESULTS: The study sample comprised 25 patients. Eleven were diagnosed with chronic HP; six had been exposed to avian proteins and five to fungal agents. Of these 11 patients, seven had positive SICs. In the 14 patients with diagnoses other than HP, all the SICs were negative. No significant differences in baseline characteristics were observed according to HP diagnosis, except in the BAL lymphocyte count. No differences were found after the test in patients diagnosed with HP; nor were there differences in baseline FeNO in patients diagnosed with HP and those who received alternative diagnoses. CONCLUSIONS: The results suggest that FeNO measurement is not useful for the diagnosis of chronic HP.
BACKGROUND: There is very little evidence of the utility of the exhaled fraction of NO (FeNO) for the diagnosis of interstitial lung disease and nearly all of it is related with connective tissue disease. Some authors have suggested that in patients with hypersensitivitypneumonitis (HP), evolution to pulmonary fibrosis may be mediated by a Th2 mechanism, which could redound in a potential utility of FeNO. The aim of this study was to investigate the values of FeNO before and after antigenic exposure with the specific inhalation challenge (SIC) and to analyze its potential utility for the diagnosis of HP. METHODS: It was a prospective, cross-sectional study of all patients older than 18 years referred to our center for suspected chronic HP between May 2012 and May 2014 and who underwent a SIC. FeNO was collected before and after SIC. RESULTS: The study sample comprised 25 patients. Eleven were diagnosed with chronic HP; six had been exposed to avian proteins and five to fungal agents. Of these 11 patients, seven had positive SICs. In the 14 patients with diagnoses other than HP, all the SICs were negative. No significant differences in baseline characteristics were observed according to HP diagnosis, except in the BAL lymphocyte count. No differences were found after the test in patients diagnosed with HP; nor were there differences in baseline FeNO in patients diagnosed with HP and those who received alternative diagnoses. CONCLUSIONS: The results suggest that FeNO measurement is not useful for the diagnosis of chronic HP.
Entities:
Keywords:
Inflammation; Interstitial lung disease; Pulmonary fibrosis; Specific inhalation challenge
Authors: Peter J Barnes; Raed A Dweik; Arthur F Gelb; Peter G Gibson; Steven C George; Hartmut Grasemann; Ian D Pavord; Felix Ratjen; Philip E Silkoff; D Robin Taylor; Noe Zamel Journal: Chest Date: 2010-09 Impact factor: 9.410
Authors: Amrita D Joshi; Daniel J Fong; Sameer R Oak; Glenda Trujillo; Kevin R Flaherty; Fernando J Martinez; Cory M Hogaboam Journal: Am J Respir Crit Care Med Date: 2009-01-16 Impact factor: 21.405
Authors: Hayley Barnes; Anna-Carin Olin; Kjell Torén; Charles McSharry; Iona Donnelly; Mona Lärstad; Carlos Iribarren; Patricia Quinlan; Paul D Blanc Journal: ERJ Open Res Date: 2020-10-05
Authors: L Torre-Bouscoulet; W R Muñoz-Montaño; D Martínez-Briseño; F J Lozano-Ruiz; R Fernández-Plata; J A Beck-Magaña; C García-Sancho; A Guzmán-Barragán; E Vergara; M Blake-Cerda; L Gochicoa-Rangel; F Maldonado; M Arroyo-Hernández; O Arrieta Journal: Respir Res Date: 2018-04-24
Authors: Paolo Cameli; Elena Bargagli; Laura Bergantini; Miriana d'Alessandro; Maria Pieroni; Giovanni A Fontana; Piersante Sestini; Rosa Metella Refini Journal: Int J Mol Sci Date: 2020-08-27 Impact factor: 5.923